Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $53.38 According to Brokerages

Urogen Pharma (NASDAQ:URGN) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $53.38.

URGN has been the subject of several analyst reports. TD Cowen raised their target price on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Urogen Pharma in a report on Monday, October 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Thursday, October 15th. Oppenheimer set a $60.00 price target on Urogen Pharma in a research note on Thursday, November 5th. Finally, UBS Group reissued an “outperform” rating on shares of Urogen Pharma in a research note on Thursday, November 5th.

Urogen Pharma Price Performance

URGN opened at $25.32 on Friday. Urogen Pharma has a fifty-two week low of $16.50 and a fifty-two week high of $50.81. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -19.18 and a beta of 1.68. The company’s 50 day moving average price is $38.08 and its two-hundred day moving average price is $31.59.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.14). The business had revenue of $89.00 million for the quarter, compared to analysts’ expectations of $89.92 million. As a group, equities research analysts predict that Urogen Pharma will post -0.36 EPS for the current year.

Insider Activity at Urogen Pharma

In related news, insider Mark Schoenberg sold 871 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total value of $37,383.32. Following the sale, the insider directly owned 59,882 shares in the company, valued at $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Chris Degnan sold 2,202 shares of the stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $36.69, for a total transaction of $80,791.38. Following the sale, the chief financial officer directly owned 4,561 shares of the company’s stock, valued at $167,343.09. This represents a 32.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 65,269 shares of company stock worth $3,037,646 over the last ninety days. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

Several large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Urogen Pharma in the second quarter valued at $117,814,000. Jefferies Financial Group Inc. acquired a new stake in Urogen Pharma during the second quarter worth approximately $80,947,000. Opaleye Management Inc. lifted its stake in Urogen Pharma by 0.7% in the second quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company’s stock valued at $52,992,000 after buying an additional 9,996 shares during the period. Bank of America Corp DE bought a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $17,506,000. Finally, Rice Hall James & Associates LLC bought a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $11,064,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.